|Articles|April 9, 2023
- Pharmaceutical Executive: April 2023
- Volume 43
- Issue 4
Pharmaceutical Executive, April 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
Unwavering Focusover 2 years ago
A Brand Game-Changer? TikTok and Pharma Marketingover 2 years ago
Does the Biotech Sector Have Reason to Be Optimistic?over 2 years ago
Kudos and Hurdles for Industry, FDA in Tackling Rare Diseasesover 2 years ago
The Payer Value Deficit in Orphan Drugsover 2 years ago
Seizing On Asia’s Opportune Market for Novel VaccinesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
